Found: 27
Select item for more details and to access through your institution.
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1419, doi. 10.1002/ajh.26686
- By:
- Publication type:
- Article
High-throughput genotyping of CRISPR/Cas9-mediated mutants using fluorescent PCR-capillary gel electrophoresis.
- Published in:
- Scientific Reports, 2015, p. 15587, doi. 10.1038/srep15587
- By:
- Publication type:
- Article
The arginase inhibitor N<sup>ω</sup>−hydroxy−nor−arginine (nor−NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target.
- Published in:
- PLoS ONE, 2018, v. 13, n. 10, p. 1, doi. 10.1371/journal.pone.0205254
- By:
- Publication type:
- Article
Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 5, p. 2863, doi. 10.3390/ijms23052863
- By:
- Publication type:
- Article
Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
- Published in:
- Nature, 2010, v. 466, n. 7307, p. 765, doi. 10.1038/nature09171
- By:
- Publication type:
- Article
CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S328, doi. 10.1016/S2152-2650(21)01769-9
- By:
- Publication type:
- Article
Poster: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S223, doi. 10.1016/S2152-2650(21)01408-7
- By:
- Publication type:
- Article
Oral Abstract: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01274-X
- By:
- Publication type:
- Article
The OPTIC Study: A Multicenter, Randomized, Phase 2 Trial to Evaluate Three Starting Doses of Ponatinib With Response-Based Dose Reduction in Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to Prior Tyrosine Kinase Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S228, doi. 10.1016/j.clml.2018.07.104
- By:
- Publication type:
- Article
Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S316, doi. 10.1016/j.clml.2017.07.117
- By:
- Publication type:
- Article
5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S307, doi. 10.1016/j.clml.2017.07.105
- By:
- Publication type:
- Article
The OPTIC Study: a Multi-Center, Randomized Phase 2 Trial with Response-Based Dose Reduction to Evaluate Three Starting Doses of Ponatinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S59, doi. 10.1016/j.clml.2016.07.086
- By:
- Publication type:
- Article
4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S56, doi. 10.1016/j.clml.2016.07.082
- By:
- Publication type:
- Article
OPTIC-2L: a Superiority Trial of Two Lower Doses of Ponatinib Versus Standard Dose Nilotinib in Second-Line Chronic Phase CML.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S60, doi. 10.1016/j.clml.2016.07.088
- By:
- Publication type:
- Article
Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia.
- Published in:
- Nature Genetics, 2014, v. 46, n. 3, p. 245, doi. 10.1038/ng.2889
- By:
- Publication type:
- Article
Gallic Acid Enhances the Efficacy of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia through Inhibition of Mitochondrial Respiration and Modulation of Oncogenic Signaling Pathways.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 14, p. 7958, doi. 10.3390/ijms25147958
- By:
- Publication type:
- Article
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
- Published in:
- British Journal of Haematology, 2007, v. 137, n. 5, p. 423, doi. 10.1111/j.1365-2141.2007.06578.x
- By:
- Publication type:
- Article
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 6, p. 1589, doi. 10.1007/s00432-019-02894-3
- By:
- Publication type:
- Article
SLC22A1-ABCB1 Haplotype Profiles Predict Imatinib Pharmacokinetics in Asian Patients with Chronic Myeloid Leukemia.
- Published in:
- PLoS ONE, 2012, v. 7, n. 12, p. 1, doi. 10.1371/journal.pone.0051771
- By:
- Publication type:
- Article
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 10, p. 1637, doi. 10.1002/cncr.29240
- By:
- Publication type:
- Article
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
- Published in:
- PLoS ONE, 2017, v. 12, n. 3, p. 1, doi. 10.1371/journal.pone.0174107
- By:
- Publication type:
- Article
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Chronic myeloid leukemia in Asia.
- Published in:
- International Journal of Hematology, 2009, v. 89, n. 1, p. 14, doi. 10.1007/s12185-008-0230-0
- By:
- Publication type:
- Article
Reply: The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.
- Published in:
- Nature Medicine, 2014, v. 20, n. 10, p. 1090, doi. 10.1038/nm.3652
- By:
- Publication type:
- Article
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
- Published in:
- Nature Medicine, 2012, v. 18, n. 4, p. 521, doi. 10.1038/nm.2713
- By:
- Publication type:
- Article